ArticleFrontiers in oncology2026

Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data.

Li Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.